A Strategic Analysis of Potential New Market Opportunities for Platform X of Firm Y

Firm Y is a biopharmaceutical firm specializing in the newly emerging business sector of RNAi Therapeutics. Firm Y is one of a few firms aspiring to bring this potential new class of human therapeutics to the market. Currently, the firm has a well-established RNAi therapeutics delivery platform, manufacturing capabilities, a stream of strategic partnerships, and development stage products in its pipeline. Firm Y wants to expand its product pipeline to give it a sustainable competitive advantage in RNAi therapeutics and ensure long-term success in its strategy to develop important new human therapeutics. The purpose of this strategic analysis is to identify new market opportunities for Firm Y for expansion of its product pipeline. The analysis is based on the company’s core competency of RNAi product delivery to the liver using its proprietary platform, PLATFORM X. First, analyses were conducted on the external industry environment and Firm Y’s internal capabilities and situation. Second, new market opportunities were identified and assessed. Third, a number of criteria were used to conduct a comprehensive evaluation of potential new markets for Firm Y. This evaluation was based on scientific and business feasibility specific to Firm Y. The results of this strategic analysis indicate that Firm Y should expand its product pipeline in a liver diseases area. The analysis further suggests that the expansion should be in the area of infectious diseases. The opportunities of interest for Firm Y within the liver diseases are Hepatitis B and Hepatitis C. The analysis also indicates Hepatocellular Carcinoma as a good next opportunity. Overall, with expansion of its product pipeline, Firm Y will show long-term growth potential for its shareholders and provide increased confidence in its ability to continue as a successful firm.